Benign Prostatic Hyperplasia – Epidemiology – Epidemiology Dashboard

DRG Epidemiology’s coverage of BPH comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of BPH for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s BPH forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BPH over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following BPH populations:

  • Total prevalent cases.
  • Diagnosed prevalent cases.
  • Lifetime DALYs gained.

Note: Coverage may vary by country.

Table of contents

  • Benign Prostatic Hyperplasia - Epidemiology - Epidemiology Dashboard
    • Introduction
      • Epidemiology Dashboard